HK inno.N and Roche 하이 로우 토토 사이트 collaborate to promote targeted anticancer drug 'Avastin'

[by Lee, Young Sung] HK inno.N announced on January 21 that it held an agreement ceremony with Roche 하이 로우 토토 사이트 at Roche 하이 로우 토토 사이트 headquarters the previous day (January 20) to jointly promote the targeted cancer drug ‘Avastin (bevacizumab)’.

As part of the agreement, HK inno.N will handle the marketing and sales of Avastin for colon cancer and gynecological cancer. Roche 하이 로우 토토 사이트 will concentrate on enhancing patient benefits through specialized research and clinical trials to improve the clinical value of Avastin, as well as exploring combination therapies with ‘Tecentriq (atezolizumab)’.

This partnership was established to meet the unmet medical needs of 하이 로우 토토 사이트n patients and extend the clinical benefits of ‘Avastin’ to a larger patient population. HK inno.N anticipates that the agreement will strengthen its business model and organizational scale, with Roche’s deep expertise in Avastin and HK inno.N’s strong sales and marketing capabilities working together to create synergies.

“After our distribution and joint sales agreements for the influenza treatments Xofluza and Tamiflu with Roche 하이 로우 토토 사이트, I am honored to announce the joint promotion of Avastin this year,” expressed Kwak Dalwon, CEO of HK inno.N. “The prevalence of colon cancer and gynecological cancer is rapidly increasing due to aging and lifestyle changes, and we are committed to working with patients and their families to fight cancer through Avastin.”

“Innovation for patients remains Roche 하이 로우 토토 사이트’s top priority,” stated Ezat Azem, CEO of Roche 하이 로우 토토 사이트. “We hope that this agreement between the two companies will create synergies and positively impact the lives of more cancer patients.”

Avastin is the first angiogenesis inhibitor that pioneered the concept of ‘starving cancer to death.’ Since receiving FDA approval in 2004, it has been prescribed to over 4.2 million cancer patients worldwide over the past 20 years, providing treatment benefits to 340,000 patients annually. In 하이 로우 토토 사이트, it was initially approved in 2005 for metastatic colorectal cancer and has since been progressively expanded its indications to include a total of 7 cancers, including non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, cervical cancer, and glioblastoma. When combined with Tecentriq, it is now used to treat a total of 8 types of cancer.